Post by CorWave

CorWave strengthens its leadership team with two key appointments 👇   We are delighted to welcome Andreas Fleischli as Chief Technology Officer and Daniel Lexcen, MS, PhD as Vice President Clinical & Scientific Affairs. 🔷 Andreas Fleischli brings about 30 years of expertise in the development of LVADs. As an internationally recognized authority in magnetically levitated pump technologies, he played a key role in pioneering and manufacturing at scale the most implanted LVAD worldwide to date, a product that has generated over $4 billion in cumulative revenues. He replaces Carl Botterbusch, who is retiring. We warmly thank Carl for his years of dedication and contribution to CorWave 🙏 🔷 Daniel Lexcen, MS, PhD joins CorWave with extensive experience in heart failure clinical research and global clinical program execution. Over the past decade, he contributed to the design and execution of numerous international clinical trials across the United States, Europe, Australia, and Japan. His experience spans the full product development lifecycle, from early clinical studies to post-market programs. Prior to joining CorWave, Daniel led the global clinical research strategy for cardiac rhythm at Medtronic.   Alongside the recent arrival of Dawn Sadlowski-Buisserez as VP of Operations, these appointments complete a leadership team capable of transitioning CorWave from a breakthrough R&D firm to a global industry leader. Read more about their journey 👉 https://lnkd.in/eWHaQVQF #CorWavers #Leadership #MedTech #Innovation #HeartFailure #LVAD